ATE355299T1 - Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung - Google Patents

Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung

Info

Publication number
ATE355299T1
ATE355299T1 AT96922458T AT96922458T ATE355299T1 AT E355299 T1 ATE355299 T1 AT E355299T1 AT 96922458 T AT96922458 T AT 96922458T AT 96922458 T AT96922458 T AT 96922458T AT E355299 T1 ATE355299 T1 AT E355299T1
Authority
AT
Austria
Prior art keywords
hif
inducible
factor
hypoxaemia
application
Prior art date
Application number
AT96922458T
Other languages
English (en)
Inventor
Gregg L Semenza
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE355299T1 publication Critical patent/ATE355299T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Communication System (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrophonic Musical Instruments (AREA)
AT96922458T 1995-06-06 1996-06-06 Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung ATE355299T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/480,473 US5882914A (en) 1995-06-06 1995-06-06 Nucleic acids encoding the hypoxia inducible factor-1

Publications (1)

Publication Number Publication Date
ATE355299T1 true ATE355299T1 (de) 2006-03-15

Family

ID=23908114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96922458T ATE355299T1 (de) 1995-06-06 1996-06-06 Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung

Country Status (9)

Country Link
US (3) US5882914A (de)
EP (2) EP0833840B1 (de)
JP (2) JPH11507541A (de)
AT (1) ATE355299T1 (de)
AU (1) AU704384B2 (de)
CA (1) CA2222279C (de)
DE (1) DE69636936T2 (de)
IL (1) IL118581A (de)
WO (1) WO1996039426A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU8536998A (en) * 1997-06-10 1998-12-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
ATE293633T1 (de) 1997-08-21 2005-05-15 Quark Biotech Inc Hypoxie-regulierte gene
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
EP1034267A1 (de) * 1997-12-04 2000-09-13 Genzyme Corporation Verbindungen und methoden zur induktion der genexpression
CA2322843A1 (en) * 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford, Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
AU5810999A (en) * 1998-08-27 2000-03-21 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants
US6436654B1 (en) * 1998-11-13 2002-08-20 Pharmacia & Upjohn Ab Methods for identifying compounds that modulate HIF-1α
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
AU7748200A (en) * 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
US20030180740A1 (en) * 2000-02-22 2003-09-25 Kingsman Alan John Differential expression screening method
CA2418386A1 (en) * 2000-08-07 2002-02-14 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US7919274B2 (en) 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2447958A1 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
ATE432346T1 (de) * 2001-06-05 2009-06-15 Masahiro Hiraoka Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003208684A1 (en) * 2002-03-05 2003-09-16 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
US20050222061A1 (en) * 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004042024A2 (en) 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
CA2509494A1 (en) * 2002-12-11 2004-06-24 University Of Massachusetts Method of introducing sirna into adipocytes
JP4546454B2 (ja) 2003-01-28 2010-09-15 レクサーン・コーポレイション Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
CA2513398C (en) * 2003-01-31 2013-09-10 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
WO2005056795A2 (en) * 2003-12-03 2005-06-23 Corgentech, Inc. Hif oligonucleotide decoy molecules
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
BRPI0515726A8 (pt) * 2004-11-09 2017-09-12 Santaris Pharma As Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
EP3146982B1 (de) 2006-10-03 2019-08-21 Genzyme Corporation Gentherapie für amyotrophe lateralsklerose und andere rückenmarkserkrankungen
AU2009213203B2 (en) * 2008-02-14 2013-06-27 Lincoln University Methods and compositions comprising Trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CA3106271A1 (en) * 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
CN113403338B (zh) 2014-03-28 2025-07-15 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
GB201601527D0 (en) 2016-01-27 2016-03-09 Univ Southampton Hif-1 and Hif-2 inhibitors
WO2021247632A1 (en) * 2020-06-02 2021-12-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer
CN116024263A (zh) * 2022-09-23 2023-04-28 龙岩学院 一种高效表达猪HIF-1α基因的真核表达载体及其构建方法
WO2024211763A1 (en) * 2023-04-05 2024-10-10 The Johns Hopkins University Synthetic mrna encoding hif-1alpha and uses for wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479948B1 (de) * 1989-06-23 1998-08-26 Genentech, Inc. Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Also Published As

Publication number Publication date
EP0833840A4 (de) 2001-12-19
EP1806357A1 (de) 2007-07-11
IL118581A0 (en) 1996-10-16
US6222018B1 (en) 2001-04-24
CA2222279A1 (en) 1996-12-12
AU704384B2 (en) 1999-04-22
EP0833840A1 (de) 1998-04-08
CA2222279C (en) 2011-02-01
EP0833840B1 (de) 2007-02-28
US5882914A (en) 1999-03-16
DE69636936D1 (de) 2007-04-12
DE69636936T2 (de) 2007-10-31
AU6332696A (en) 1996-12-24
JP2009077729A (ja) 2009-04-16
IL118581A (en) 2000-01-31
WO1996039426A1 (en) 1996-12-12
US6020462A (en) 2000-02-01
JPH11507541A (ja) 1999-07-06

Similar Documents

Publication Publication Date Title
DE69636936D1 (de) Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung
DE69403610D1 (de) Verfahren zur Herstellung von Ameisensäure und ihren Derivaten
AT362780B (de) Verfahren zur herstellung von neuen substituierten aminosaeuren bzw. deren estern und ihren salzen
DE3687103D1 (de) Verfahren zur herstellung von n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanyl-l-proline.
DE69221765D1 (de) Verfahren zur Herstellung von Polybutadien
DE69714663D1 (de) Verfahren zur Herstellung von Polybutadien
ATE141923T1 (de) Verfahren zur abtrennung von metallorganischen verbindungen und/oder metallcarbonylen aus ihren lösungen in organischen medien
DE3680632D1 (de) Verfahren zur herstellung von kohlenstoffasern und diese kohlenstoffasern.
DE3682353D1 (de) Anordnung und verfahren zur erzeugung verschiedener videowischraender.
DE69508722D1 (de) Verfahren zur Herstellung von Carbonsäuren durch Oxydation der entsprechenden Alkane
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
DE69419238D1 (de) Polyimidvorläufer-Zusammensetzung, Polyimid-Zusammensetzung und Verfahren zur Herstellung dieser Polyimid-Zusammensetzung
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
DE69314779D1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
AT377974B (de) Verfahren zur herstellung von neuen aromatischen carbonsaeuren und ihren salzen
ATE108174T1 (de) Verfahren zur herstellung von r(+)-aminocarnitin und s(-)-aminocarnitin.
DE59606111D1 (de) Verfahren zur Herstellung von Carbonsäuren durch Carbonylierung von Olefinen
DE69313297D1 (de) Benzofuranone, benzodifurantrione und verfahren zur herstellung von benzodifurandionen
EP0171707A3 (de) Verfahren zur Herstellung von Polyimidestern der Trimellitsäure
DE3688854D1 (de) Verfahren zur herstellung von polythiobisphenolen und verfahren zur herstellung von mercaptophenolen durch hydrogenolyse der polythiobisphenole.
DE69433687D1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
DE3786134D1 (de) Verfahren zur herstellung von polyamidsaeure mit siloxanbindungen und von polyimid mit siloxanbindungen und isoindolochinazolindion-ringen.
DE3675623D1 (de) Verfahren zur fermentativen herstellung von l-aminosaeuren aus alpha-ketocarbonsaeuren.
ATE150765T1 (de) Neue peptide, deren intermediate, verfahren zu deren herstellung, antiallergische agenzien, vasodilatoren und immunoregulatoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties